On May, 11 Analysts See $-0.98 EPS for Eiger BioPharmaceuticals, Inc. (EIGR)

April 17, 2018 - By Nellie Rakes

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Corporate Logo

On May, 11 WallStreet expected Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s earnings report, according to RTT. This year’s EPS analyst estimate is expected to be $-0.98. That is 26.87 % up compareed to $-1.34 EPS for last year. -11.71 % EPS growth is what Wall Street’s sees after $-1.11 reported EPS last quarter. On during the last trading session the stock increased $0.15 or 1.38%, reaching $11.Eiger BioPharmaceuticals, Inc. has volume of 95,812 shares. Since April 17, 2017 EIGR has declined 11.57% and is downtrending. EIGR underperformed by 23.12% the S&P500.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States.The firm is worth $115.79 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.Currently it has negative earnings.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.